Clinical trial
Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00002911 · ILEX Oncology Services, Incorporated, Industry · Completed
Key facts
| NCT number | NCT00002911 |
|---|---|
| Title | Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer |
| Official title | A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MARIMASTAT IN PATIENTS WITH MINIMAL DISEASE STAGE III NON-SMALL CELL LUNG CANCER |
| Lead sponsor | ILEX Oncology Services, Incorporated, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | marimastat |
| Start date | Dec 1, 1996 |
| Completion | May 1, 2004 |
| First posted | May 26, 2004 |
| Last update posted | Dec 18, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: